304 related articles for article (PubMed ID: 33942483)
21. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
22. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
[TBL] [Abstract][Full Text] [Related]
23. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
24. Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer.
Zhang J; Yang J; Lin C; Liu W; Huo Y; Yang M; Jiang SH; Sun Y; Hua R
Theranostics; 2020; 10(18):8400-8414. PubMed ID: 32724477
[No Abstract] [Full Text] [Related]
25. Single-cell transcriptome reveals the heterogeneity of malignant ductal cells and the prognostic value of REG4 and SPINK1 in primary pancreatic ductal adenocarcinoma.
Ji Y; Xu Q; Wang W
PeerJ; 2024; 12():e17350. PubMed ID: 38827297
[TBL] [Abstract][Full Text] [Related]
26. Cystatin F as a key family 2 cystatin subunit and prognostic biomarker for early‑stage pancreatic ductal adenocarcinoma.
Yang C; Yu T; Liu Z; Ye X; Liao X; Wang X; Han C; Zhu G; Qin W; Peng T
Oncol Rep; 2019 Jul; 42(1):79-90. PubMed ID: 31059105
[TBL] [Abstract][Full Text] [Related]
27. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
[TBL] [Abstract][Full Text] [Related]
28. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma.
Li F; Si W; Xia L; Yin D; Wei T; Tao M; Cui X; Yang J; Hong T; Wei R
Mol Cancer; 2024 May; 23(1):90. PubMed ID: 38711083
[TBL] [Abstract][Full Text] [Related]
29. P4HA1/HIF1α feedback loop drives the glycolytic and malignant phenotypes of pancreatic cancer.
Cao XP; Cao Y; Li WJ; Zhang HH; Zhu ZM
Biochem Biophys Res Commun; 2019 Aug; 516(3):606-612. PubMed ID: 31239153
[TBL] [Abstract][Full Text] [Related]
30. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
31. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA-891b is an independent prognostic factor of pancreatic cancer by targeting Cbl-b to suppress the growth of pancreatic cancer cells.
Dong Q; Li C; Che X; Qu J; Fan Y; Li X; Li Y; Wang Q; Liu Y; Yang X; Qu X
Oncotarget; 2016 Dec; 7(50):82338-82353. PubMed ID: 27494897
[TBL] [Abstract][Full Text] [Related]
33. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance.
Ma MZ; Kong X; Weng MZ; Cheng K; Gong W; Quan ZW; Peng CH
J Exp Clin Cancer Res; 2013 Sep; 32(1):71. PubMed ID: 24289824
[TBL] [Abstract][Full Text] [Related]
34. Establishing and validating an ADCP-related prognostic signature in pancreatic ductal adenocarcinoma.
Zhang D; Cui F; Peng L; Wang M; Yang X; Xia C; Li K; Yin H; Zhang Y; Yu Q; Jin Z; Huang H
Aging (Albany NY); 2022 Aug; 14(15):6299-6315. PubMed ID: 35963640
[TBL] [Abstract][Full Text] [Related]
35. A potential prognostic marker and therapeutic target: SPOCK1 promotes the proliferation, metastasis, and apoptosis of pancreatic ductal adenocarcinoma cells.
Li J; Ke J; Fang J; Chen JP
J Cell Biochem; 2020 Jan; 121(1):743-754. PubMed ID: 31478239
[TBL] [Abstract][Full Text] [Related]
36. Identification of a robust functional subpathway signature for pancreatic ductal adenocarcinoma by comprehensive and integrated analyses.
Wang P; Zhang C; Li W; Zhai B; Jiang X; Reddy S; Jiang H; Sun X
Cell Commun Signal; 2020 Mar; 18(1):34. PubMed ID: 32122386
[TBL] [Abstract][Full Text] [Related]
37. Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Kubo M; Gotoh K; Eguchi H; Kobayashi S; Iwagami Y; Tomimaru Y; Akita H; Asaoka T; Noda T; Takeda Y; Tanemura M; Mori M; Doki Y
Ann Surg Oncol; 2020 Feb; 27(2):610-619. PubMed ID: 31605325
[TBL] [Abstract][Full Text] [Related]
38. Elevated glypican-1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma.
Lu H; Niu F; Liu F; Gao J; Sun Y; Zhao X
Cancer Med; 2017 Jun; 6(6):1181-1191. PubMed ID: 28440066
[TBL] [Abstract][Full Text] [Related]
39. Construction and validation of a novel immunological model to predict prognosis in pancreatic ductal adenocarcinoma.
Liu J; He M
Int Immunopharmacol; 2024 Jun; 134():112266. PubMed ID: 38761784
[TBL] [Abstract][Full Text] [Related]
40. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
